Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) EBT (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed EBT for 14 consecutive years, with -$29.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT rose 27.19% year-over-year to -$29.9 million, compared with a TTM value of -$133.8 million through Dec 2025, down 48.2%, and an annual FY2025 reading of -$3.6 million, down 4616.25% over the prior year.
  • EBT was -$29.9 million for Q4 2025 at Karyopharm Therapeutics, down from -$25.7 million in the prior quarter.
  • Across five years, EBT topped out at $38.6 million in Q4 2021 and bottomed at -$57.3 million in Q1 2021.
  • Average EBT over 5 years is -$32.8 million, with a median of -$36.8 million recorded in 2022.
  • The sharpest move saw EBT surged 715.52% in 2021, then crashed 246.7% in 2025.
  • Year by year, EBT stood at $38.6 million in 2021, then tumbled by 199.57% to -$38.4 million in 2022, then dropped by 9.16% to -$42.0 million in 2023, then increased by 2.27% to -$41.0 million in 2024, then increased by 27.19% to -$29.9 million in 2025.
  • Business Quant data shows EBT for KPTI at -$29.9 million in Q4 2025, -$25.7 million in Q3 2025, and -$35.0 million in Q2 2025.